keyword
MENU ▼
Read by QxMD icon Read
search

ILD on rheumatoid arthritis

keyword
https://www.readbyqxmd.com/read/28495692/shared-genetic-predisposition-in-rheumatoid-arthritis-interstitial-lung-disease-and-familial-pulmonary-fibrosis
#1
Pierre-Antoine Juge, Raphaël Borie, Caroline Kannengiesser, Steven Gazal, Patrick Revy, Lidwine Wemeau-Stervinou, Marie-Pierre Debray, Sébastien Ottaviani, Sylvain Marchand-Adam, Nadia Nathan, Gabriel Thabut, Christophe Richez, Hilario Nunes, Isabelle Callebaut, Aurélien Justet, Nicolas Leulliot, Amélie Bonnefond, David Salgado, Pascal Richette, Jean-Pierre Desvignes, Huguette Lioté, Philippe Froguel, Yannick Allanore, Olivier Sand, Claire Dromer, René-Marc Flipo, Annick Clément, Christophe Béroud, Jean Sibilia, Baptiste Coustet, Vincent Cottin, Marie-Christophe Boissier, Benoit Wallaert, Thierry Schaeverbeke, Florence Dastot le Moal, Aline Frazier, Christelle Ménard, Martin Soubrier, Nathalie Saidenberg, Dominique Valeyre, Serge Amselem, Catherine Boileau, Bruno Crestani, Philippe Dieudé
Despite its high prevalence and mortality, little is known about the pathogenesis of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Given that familial pulmonary fibrosis (FPF) and RA-ILD frequently share the usual pattern of interstitial pneumonia and common environmental risk factors, we hypothesised that the two diseases might share additional risk factors, including FPF-linked genes. Our aim was to identify coding mutations of FPF-risk genes associated with RA-ILD.We used whole exome sequencing (WES), followed by restricted analysis of a discrete number of FPF-linked genes and performed a burden test to assess the excess number of mutations in RA-ILD patients compared to controls...
May 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28444364/effect-of-rituximab-on-the-progression-of-rheumatoid-arthritis-related-interstitial-lung-disease-10-years-experience-at-a-single-centre
#2
Md Yuzaiful Md Yusof, Angela Kabia, Michael Darby, Giovanni Lettieri, Paul Beirne, Edward M Vital, Shouvik Dass, Paul Emery
Objective.: To evaluate the effect of rituximab (RTX) in patients with RA-related interstitial lung disease (RA-ILD) and identify factors associated with outcome after treatment. Methods.: An observational study of patients with RA-ILD was conducted from a cohort of RTX-treated RA patients in a single centre for >10 years. Progression was defined by any of the following: a decrease of pre-RTX forced vital capacity (FVC) >10% or diffusion capacity of carbon monoxide (DLCO) >15% predicted, worsening of the ILD score or death from progressive ILD...
April 24, 2017: Rheumatology
https://www.readbyqxmd.com/read/28352064/clinical-characteristics-associated-with-occurrence-and-poor-prognosis-of-interstitial-lung-disease-in-rheumatoid-arthritis
#3
Ji Ae Yang, Jeong Seok Lee, Jin Kyun Park, Eun Bong Lee, Yeong Wook Song, Eun Young Lee
Background/Aims: To analyze clinical characteristics of interstitial lung disease (ILD) associated with rheumatoid arthritis (RA), especially in patients with poor prognosis. Methods: Seventy-seven RA patients with ILD and 231 age, sex, and disease duration-matched RA patients without ILD were enrolled in this retrospective study. Epidemiologic, clinical, and laboratory information were obtained through a medical chart review. Logistic regression analysis was used to estimate the risk of mortality in RA patients with ILD...
March 28, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/28207496/recent-advances-in-the-pathogenesis-prediction-and-management-of-rheumatoid-arthritis-associated-interstitial-lung-disease
#4
Cheilonda Johnson
PURPOSE OF REVIEW: To provide an overview of recently published articles covering interstitial lung disease associated with rheumatoid arthritis (RA-ILD). RECENT FINDINGS: Over the past year, many studies replicated previous findings in more diverse and occasionally larger populations internationally. Specifically, the association among cigarette smoking, high rheumatoid factor titer, elevated anticitrullinated protein antibody (ACPA) levels, and RA-ILD was strengthened...
May 2017: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/28191607/retrospective-study-of-the-clinical-characteristics-and-risk-factors-of-rheumatoid-arthritis-associated-interstitial-lung-disease
#5
Yongfeng Zhang, Hongbin Li, Nawei Wu, Xin Dong, Yi Zheng
This study aims to explore the clinical characteristics and risk factors of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD). This is a retrospective study of 550 patients with RA. All patients underwent chest high-resolution computed tomography (HRCT) scanning. (1) Two hundred thirty-seven out of five hundred fifty (43.1%) patients with RA were diagnose with ILD. 13.5% ILD occurred before RA onset, 69.6% ILD occurred within 10 years of RA onset, and 16.9% ILD occurred more than 10 years after RA onset...
February 12, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28117616/biologics-induced-interstitial-lung-diseases-in-rheumatic-patients-facts-and-controversies
#6
Juan Chen, Shuhong Chi, Feng Li, Jiali Yang, William C Cho, Xiaoming Liu
Interstitial lung disease (ILD) is a common, devastating pulmonary complication. An increased number of reports suggesting that biological disease modifying antirheumatic drugs (DMARDs) induced or exacerbated ILDs in rheumatoid arthritis (RA) patients has garnered increased attention. Areas covered: This article discusses ILDs induced by or exacerbated during biological therapy in RA patients. The article summarizes the efficacy and safety of a variety of licensed and off-label biologics clinically used for rheumatic diseases, focusing on the onset or exacerbation of RA-associated ILDs (RA-ILDs) in RA patients treated with biologics targeting tumor necrosis factor, CD20, interleukin 1 (IL-1) and IL-6 receptors...
March 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28103855/plasma-mirna-expression-profiles-in-rheumatoid-arthritis-associated-interstitial-lung-disease
#7
Shomi Oka, Hiroshi Furukawa, Kota Shimada, Atsushi Hashimoto, Akiko Komiya, Naoshi Fukui, Naoyuki Tsuchiya, Shigeto Tohma
BACKGROUND: Interstitial lung disease (ILD) is frequently associated with rheumatoid arthritis (RA), and is designated RA-associated ILD (RA-ILD). RA-ILD has a large impact on the prognosis of RA. Here, we investigated the micro RNAs (miRNAs) profiles to determine whether they may be useful for diagnosing RA-ILD. METHODS: RNA was isolated from plasma samples and cDNA was synthesized. Real-time RT-PCR analysis was performed to evaluate 752 miRNA expression profiles in plasma pools from RA patients with or without RA-ILD...
January 19, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/27733490/therapeutic-management-of-patients-with-rheumatoid-arthritis-and-associated-interstitial-lung-disease-case-report-and-literature-review
#8
Andrea Picchianti Diamanti, Milica Markovic, Giuseppe Argento, Simonetta Giovagnoli, Alberto Ricci, Bruno Laganà, Raffaele D'Amelio
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that can present different extrarticular manifestations involving heart, lungs and kidneys. In recent years there has been a growing awareness of the central role played by the lungs in the onset and progression of RA. In particular interstitial lung disease (ILD) is a common pulmonary manifestation that may be related to the inflammatory process itself, infectious complications and to the treatments used. Management of patients with ILD/RA is still a challenge for clinicians, both synthetic [mainly methotrexate (MTX), leflunomide] and biologic immunosuppressors [mainly anti-tumor necrosis factor (TNF)α] have in fact been related to the onset or worsening of lung diseases with conflicting data...
January 2017: Therapeutic Advances in Respiratory Disease
https://www.readbyqxmd.com/read/27609750/rheumatoid-arthritis-associated-autoantibodies-and-subclinical-interstitial-lung-disease-the-multi-ethnic-study-of-atherosclerosis
#9
Elana J Bernstein, R Graham Barr, John H M Austin, Steven M Kawut, Ganesh Raghu, Jessica L Sell, Eric A Hoffman, John D Newell, Jubal R Watts, P Hrudaya Nath, Sushil K Sonavane, Joan M Bathon, Darcy S Majka, David J Lederer
BACKGROUND: Adults with interstitial lung disease (ILD) often have serologic evidence of autoimmunity of uncertain significance without overt autoimmune disease. We examined associations of rheumatoid arthritis (RA)-associated antibodies with subclinical ILD in community-dwelling adults. METHODS: We measured serum rheumatoid factor (RF) and anticyclic citrullinated peptide antibody (anti-CCP) and high attenuation areas (HAAs; CT attenuation values between -600 and -250 Hounsfield units) on cardiac CT in 6736 community-dwelling US adults enrolled in the Multi-Ethnic Study of Atherosclerosis...
December 2016: Thorax
https://www.readbyqxmd.com/read/27421215/connective-tissue-disease-related-interstitial-lung-disease
#10
REVIEW
M Kristen Demoruelle, Shikha Mittoo, Joshua J Solomon
Interstitial lung disease (ILD) is commonly present in patients with an underlying connective tissue disease (CTD), particularly those with systemic sclerosis, rheumatoid arthritis, and inflammatory myositis. The clinical spectrum can range from asymptomatic findings on imaging to respiratory failure and death. Distinguishing features in the clinical, radiographic, and histopathologic characteristics of CTD-ILD subsets can predict prognosis and treatment response. Treatment often consists of combinations of immunosuppressive medications, but there is a paucity of guidance in the literature to help clinicians determine appropriate screening and management of CTD-ILD...
February 2016: Best Practice & Research. Clinical Rheumatology
https://www.readbyqxmd.com/read/27368035/diffuse-alveolar-damage-in-a-patient-with-rheumatoid-arthritis-under-prolonged-leflunomide-treatment-a-case-report-and-literature-review
#11
REVIEW
Li-Ta Keng, Mong-Wei Lin, Hsien-Neng Huang, Kuei-Pin Chung
Patients with rheumatoid arthritis (RA) often have pulmonary involvement, and interstitial lung disease (ILD) is the primary manifestation, in which diffuse alveolar damage (DAD) is a rare histopathologic pattern. Leflunomide (LEF) is a frequently prescribed disease-modifying antirheumatic drug for treating RA. LEF-related ILD in the form of DAD has been reported in patients with RA, with the duration of LEF treatment before symptom onset ranging from 6 to 1204 days.We present a case of elderly woman with RA under prolonged LEF treatment for >9 years (3291 days), who had acute respiratory failure with the initial presentation of exertional dyspnea, fever, chills, and productive cough for 2 days...
June 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27339212/increased-serum-kl-6-levels-induced-by-pulmonary-mycobacterium-avium-complex-infection-in-a-patient-with-ra-associated-lung-disease
#12
Koichi Waseda, Kazuki Ocho, Kou Hasegawa, Kosuke Kimura, Masaya Iwamuro, Yoshihisa Hanayama, Eisei Kondo, Nobuaki Miyahara, Fumio Otsuka
KL-6 is a glycoprotein found predominantly on type II pneumocytes and alveolar macrophages, and often shows increased serum levels in patients with interstitial pneumonia. We report a case of mycobacterium avium complex (MAC) infection whose disease activity was correlated with KL-6 levels in serum. During treatment of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) with prednisolone, chest image findings improved in association with decreased KL-6 levels. Following tapering of prednisolone, chest image findings deteriorated again as levels of KL-6 increased, suggesting recurrence of RA-ILD...
June 2016: Acta Medica Okayama
https://www.readbyqxmd.com/read/27279757/up-to-date-information-on-rheumatoid-arthritis-associated-interstitial-lung-disease
#13
REVIEW
Takafumi Suda
Pulmonary involvement is common in rheumatoid arthritis (RA) and affects all the components of the lung. Interstitial lung disease (ILD) is the most predominant pulmonary manifestation and has been identified as the main cause of morbidity and mortality in RA. Clinically significant RA-ILD occurs in approximately 10% of RA patients. Several risk factors, such as old age, male gender, and smoking, have been reported to date. Histologically, the proportion of the usual interstitial pneumonia (UIP) pattern is higher in RA-ILD than in ILD associated with other connective tissue diseases, and RA-ILD also shows nonspecific interstitial pneumonia and organizing pneumonia patterns...
2015: Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine
https://www.readbyqxmd.com/read/27231868/connective-tissue-disease-associated-interstitial-lung-diseases-unresolved-issues
#14
Irene Jarana Aparicio, Joyce S Lee
Interstitial lung disease (ILD) complicating connective tissue disorders, such as scleroderma and rheumatoid arthritis, is associated with significant morbidity and mortality. Progress has been made in our understanding of these collective diseases; however, there are still many unanswered questions. In this review, we describe the current views on epidemiology, clinical presentation, treatment, and prognosis in patients with connective tissue disease (CTD)-associated ILD. We also highlight several areas that remain unresolved and in need of further investigation, including interstitial pneumonia with autoimmune features, histopathologic phenotype, and pharmacologic management...
June 2016: Seminars in Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/27142966/efficacy-of-intensive-immunosuppression-in-exacerbated-rheumatoid-arthritis-associated-interstitial-lung-disease
#15
Mineto Ota, Yukiko Iwasaki, Hiroaki Harada, Oh Sasaki, Yasuo Nagafuchi, Shinichiro Nakachi, Shuji Sumitomo, Hirofumi Shoda, Shigeto Tohma, Keishi Fujio, Kazuhiko Yamamoto
OBJECTIVES: Acute or subacute exacerbations are recognized as a severe complication of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Nevertheless, the role of intensive immunosuppression in RA-ILD remains elusive. We attempted to evaluate the clinical characteristics and efficacy of immunosuppressive treatment in exacerbated RA-ILD. METHODS: Clinical data, including respiratory function, imaging, treatment, and prognosis, were retrospectively collected for 17 patients with RA-ILD who required hospitalization at the University of Tokyo Hospital due to an acute exacerbation (12 patients) or subacute exacerbation (5 patients)...
January 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/27094018/mean-pulmonary-arterial-pressure-as-a-prognostic-indicator-in-connective-tissue-disease-associated-with-interstitial-lung-disease-a-retrospective-cohort-study
#16
Kota Takahashi, Hiroyuki Taniguchi, Masahiko Ando, Koji Sakamoto, Yasuhiro Kondoh, Naohiro Watanabe, Tomoki Kimura, Kensuke Kataoka, Atsushi Suzuki, Satoru Ito, Yoshinori Hasegawa
BACKGROUND: Pulmonary hypertension (PH) can develop in connective tissue disease associated interstitial lung disease (CTD-ILD), and contributes to increased morbidity and mortality. However, except for systemic sclerosis and mixed connective tissue disease, the impact of mean pulmonary arterial pressure (MPAP) on survival in CTD-ILD has not been sufficiently elucidated. We hypothesized that pulmonary arterial pressure may be a prognostic factor in CTD-ILDs regardless of the kind of CTD...
April 19, 2016: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/27072347/association-of-disease-activity-with-acute-exacerbation-of-interstitial-lung-disease-during-tocilizumab-treatment-in-patients-with-rheumatoid-arthritis-a-retrospective-case-control-study
#17
Mitsuhiro Akiyama, Yuko Kaneko, Kunihiro Yamaoka, Harumi Kondo, Tsutomu Takeuchi
The objective of the study was to identify risk factors for acute exacerbation of interstitial lung disease (ILD) during tocilizumab treatment in patients with rheumatoid arthritis (RA). This is a retrospective, case-control study. We reviewed 395 consecutive RA patients who received tocilizumab. First, we divided the patients according to the presence (RA-ILD) or absence of ILD (non-ILD) assessed by chest X-ray or high-resolution computed tomography, and compared them for characteristics relevant to RA-ILD...
June 2016: Rheumatology International
https://www.readbyqxmd.com/read/27050433/smoking-and-subclinical-ild-in-ra-versus-the-multi-ethnic-study-of-atherosclerosis
#18
Cheilonda Johnson, Jon T Giles, Joan Bathon, David Lederer, Eric A Hoffman, R Graham Barr, Sonye K Danoff
A population-based cohort showed an association between cigarette smoking and subclinical parenchymal lung disease defined as regions of increased computed tomography (CT) lung densitometry. This technique has not been applied to the rheumatoid arthritis (RA) population where associated ILD is highly prevalent. The association between cumulative cigarette smoking and volume of areas of high attenuation (HAA: >-600 and <-250 Hounsfield Units) on full inspiratory CT was compared in 172 RA participants and 3,969 controls in a general population sample...
2016: PloS One
https://www.readbyqxmd.com/read/27027811/management-of-connective-tissue-diseases-associated-interstitial-lung-disease-a-review-of-the-published-literature
#19
REVIEW
Beth Wallace, Dharshan Vummidi, Dinesh Khanna
PURPOSE OF REVIEW: Interstitial lung disease (ILD), though a common and often a severe manifestation of many connective tissue diseases (CTD), is challenging to manage because of its variable presentation and the relative lack of guidelines to assist the clinician. In this review, we discuss the approach to diagnosis, treatment, and monitoring patients with CTD-associated ILD, with a focus on systemic sclerosis (SSc), rheumatoid arthritis (RA), and idiopathic inflammatory myopathy (IIM)...
May 2016: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/26921132/the-use-of-auto-antibody-testing-in-the-evaluation-of-interstitial-lung-disease-ild-a-practical-approach-for-the-pulmonologist
#20
REVIEW
Thomas Bahmer, Micaela Romagnoli, Francesco Girelli, Martin Claussen, Klaus F Rabe
Interstitial lung diseases (ILD), also defined as diffuse parenchymal lung diseases (DPLD) include a heterogeneous group of pulmonary disorders. They may be caused by an underlying connective tissue disease (CTD), Rheumatoid Arthritis (RA) or ANCA-associated Vasculitis (AAV). Pulmonary manifestations of these conditions may also precede systemic onset and therefore, pulmonologists may be confronted with diagnosing a systemic rheumatic disease. For the discrimination of CTD-related ILD and idiopathic interstitial pneumonia (IIP), serological testing is recommended...
April 2016: Respiratory Medicine
keyword
keyword
113530
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"